1.Adjuvant chemotherapy for stage II colon cancer.
Chinese Journal of Gastrointestinal Surgery 2012;15(10):1092-1094
Colorectal cancer is one of the most common diseases in China. Whether stage 11 patients should receive adjuvant chemotherapy was controversial. Here we summarize the latest advancement about clinical risk factors and biomarkers for the adjuvant chemotherapy of stage 11 colon cancer.
Chemotherapy, Adjuvant
;
China
;
Colonic Neoplasms
;
drug therapy
;
pathology
;
Humans
;
Neoplasm Staging
;
Risk Factors
2.Neoadjuvant immunotherapy for colorectal cancer.
Chinese Journal of Gastrointestinal Surgery 2023;26(1):58-67
Immunotherapy has been one of the hot topics in the field of colorectal cancer research in recent years. Patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) are the main beneficiaries of immunotherapy. The response rate of patients with dMMR/MSI-H colorectal cancer receiving neoadjuvant immunotherapy is nearly 100%, of which the pathological complete response rate approximately accounts for 60%-67%. The prospect of neoadjuvant immunotherapy in dMMR or MSI-H colorectal cancer patients, especially in the rectal cancer patients, lies in achieving sustainable clinical complete response so as to achieve organ preservation and avoid adverse effects on reproductive, sexual, bowel and bladder function after surgery and radiotherapy. Studies have shown that part of the colorectal cancer patients of microsatellite stability (MSS) or mismatch repair proficient (pMMR) can respond to neoadjuvant immunotherapy in combination with other treatment methods such as radiotherapy and chemotherapy. In pMMR or MSS colorectal cancer, optimizing neoadjuvant immunotherapy regimens and finding effective efficacy prediction biomarkers are important research directions. In neoadjuvant immunotherapy, overcoming primary and secondary resistance and identifying the pseudoprogression and hyperprogression of neoadjuvant immunotherapy are clinical challenges that require attention. This paper comprehensively reviews the research progress, controversies,challenges and future research directions of neoadjuvant immunotherapy (mainly immune checkpoint inhibitors) in colorectal cancer.
Humans
;
Neoadjuvant Therapy/methods*
;
Colorectal Neoplasms/drug therapy*
;
Colonic Neoplasms/pathology*
;
Immunotherapy/methods*
;
DNA Mismatch Repair
;
Microsatellite Instability
3.Solitary Extramedullary Plasmacytoma in the Gastrointestinal Tract: Report of Two Cases and Review of Literature.
You Jin HAN ; Seun Ja PARK ; Moo In PARK ; Won MOON ; Sung Eun KIM ; Ki Hwan KU ; So Young OCK
The Korean Journal of Gastroenterology 2014;63(5):316-320
Solitary extramedullary plasmacytoma (EMP) is a plasma cell neoplasm without bone marrow involvement. EMPs are rare in the gastrointestinal (GI) tract. We report two cases of primary EMP, one in the transverse colon and the other in the stomach. In the first case, a mass on the transverse colon was found on colonoscopy. The patient underwent left hemicolectomy and has been followed-up for 3 years without recurrence postoperatively. The latter case had several masses in the stomach. The patient underwent bypass surgery and has received supportive care for 1 month. Histopathologic specimens of both the cases showed a monoclonal lambda chain EMP. Subsequent investigations included a bone marrow biopsy, serum IgA, IgG, IgM and serum protein electrophoresis, and the results were negative for multiple myeloma in both the cases. Solitary EMP in the GI tract can be mistaken for colon cancer or stomach cancer on endoscopy; therefore, a sufficient number of biopsy specimens can help diagnose solitary EMPs. Surgical resection alone or with radiation therapy in cases with positive surgical margin is currently the only treatment for solitary EMP in the GI tract. Further study is necessary to determine disease prognosis and to investigate other treatment methods.
Colonic Neoplasms/*diagnosis/pathology/therapy
;
Endoscopy, Gastrointestinal
;
Humans
;
Immunohistochemistry
;
Male
;
Middle Aged
;
Plasmacytoma/*diagnosis/pathology/therapy
;
Positron-Emission Tomography
;
Stomach Neoplasms/*diagnosis/pathology/therapy
;
Tomography, X-Ray Computed
4.Immune checkpoint inhibitors in the treatment of colorectal cancer: a review of clinical trials.
Chinese Journal of Gastrointestinal Surgery 2022;25(3):205-213
Colorectal cancer is the third most common cancer in the world. The treatments include surgery, chemotherapy, radiotherapy and targeted therapy. The guidelines of many tumor types have been rewritten with the advent of immune checkpoint inhibitors. There are significant differences in the efficacy of immune checkpoint inhibitors in colorectal cancer according to microsatellite status. Microsatellite instability-high (MSI-H) colorectal cancer has made a breakthrough in immunotherapy, whether in the late-line, first-line, adjuvant or neoadjuvant therapy. The success of KEYNOTE-177 study has changed the guidelines with pembrolizumab becoming a standard treatment in the first-line treatment of MSI-H advanced colorectal cancer. The NICHE study, which used immunotherapy as neoadjuvant treatment of colorectal cancer, has made exciting achievements in MSI-H colorectal cancer. For microsatellite stability (MSS) colorectal cancer, many studies are ongoing, and immunotherapy is still unable to challenge the status of traditional treatment. In this paper, we review the clinical trials related to immune checkpoint inhibitors of colorectal cancer, expecting to provide references for the development of colorectal cancer immunotherapy.
Clinical Trials as Topic
;
Colonic Neoplasms/drug therapy*
;
Colorectal Neoplasms/pathology*
;
Humans
;
Immune Checkpoint Inhibitors/therapeutic use*
;
Immunotherapy
5.Occurrence of colonic liposarcoma after retroperitoneal liposarcoma.
Jin Hwa CHOI ; In Gyu HWANG ; Seong Jae CHA ; Tae Jin LEE ; Joung Soon JANG
The Korean Journal of Internal Medicine 2015;30(1):125-128
No abstract available.
Aged
;
Biopsy
;
Chemotherapy, Adjuvant
;
Colectomy
;
Colonic Neoplasms/*pathology/therapy
;
Humans
;
Liposarcoma/*pathology/therapy
;
Male
;
Neoplasms, Second Primary/*pathology/therapy
;
Radiotherapy, Adjuvant
;
Retroperitoneal Neoplasms/*pathology/therapy
;
Time Factors
;
Tomography, X-Ray Computed
;
Treatment Outcome
6.Effect of jinfu kang to experimental precancerous colon lesions and urinary metabolites in rat.
Yin-ping QIU ; Ming-ming SU ; Da-zheng WU ; Ai-hua ZHAO ; Yu-min LIU ; Wei JIA
China Journal of Chinese Materia Medica 2008;33(22):2653-2657
OBJECTIVE: To profile urinary metabolite variations from 1, 2-dimethylhydrazine (DMH)-induced precancerous colon rats, Jinfu Kang treated rats and healthy controls.
METHODWe used ethyl chloroformate derivatization and gas chromatography-mass spectrometry (GC-MS) based metabonomic method to analyze rat urines.
RESULTThe time-dependent variations of metabolite profile showed a progressive deviation of the metabolism in the model group from the initial pattern over time and a systemic recovery of the metabolism in the treatment group, which is consistent with the histological results. The in-depth analysis indicated that the disorder of tricarboxylic acid cycle (TCA), tryptophan metabolism, polyamine metabolism and gut flora structure were associated with DMH intervention.
CONCLUSIONMetabolic study revealed that Jinfu Kang can effectively reverse metabolic departures in DMH-induced precancerous colon rat, which is consistent with pathological results.
Animals ; Colonic Neoplasms ; chemically induced ; pathology ; Colonic Polyps ; chemically induced ; drug therapy ; urine ; Dimethylhydrazines ; pharmacology ; Drugs, Chinese Herbal ; pharmacology ; Gas Chromatography-Mass Spectrometry ; Male ; Rats ; Rats, Wistar
7.Retroviral endostatin gene transfer inhibits human colon cancer cell growth in vivo.
Weichang CHEN ; Jianxin FU ; Qiang LIU ; Changgeng RUAN ; Shudong XIAO
Chinese Medical Journal 2003;116(10):1582-1584
OBJECTIVETo investigate the therapeutic effect of retroviral endostatin gene transfer on the human colon cancer cell line, LoVo.
METHODSA retroviral vector pLESSN expressing secretable endostatin was constructed and packaged with a titer of 8.2 x 10(5) CFU/ml. A LoVo cell line was subjected to retrovirus-mediated endostatin gene transfer. The proviral integration of endostatin was analyzed with PCR. The function of endostatin was tested by MTT assay in vitro and a mouse xenograft model in vivo.
RESULTSAfter transfection and superinfection, amphotropic retrovirus was collected, and transduction with amphotropic retroviruses resulted in endostatin proviral integration. The endostatin secreted by transduced LoVo cells markedly inhibited cell growth up to 67% (P<0.001), compared with the control cells. The gene expression of endostatin in LoVo colon tumor cells significantly inhibited tumor growth in vivo. There was an 86% reduction in tumor size in the endostatin-transduced group, accompanied by a reduction in vessels, compared with the control group (P<0.01).
CONCLUSIONRetroviruses can allow functional expression of the endostatin gene in human colon tumors, showing promise for an antitumor strategy using antiangiogenesis.
Cell Division ; Cell Line, Tumor ; Colonic Neoplasms ; pathology ; therapy ; Endostatins ; genetics ; Gene Transfer Techniques ; Genetic Vectors ; Humans ; Retroviridae
8.Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.
Siriwan TANGJITGAMOL ; Jakkapan KHUNNARONG ; Sunamchok SRIJAIPRACHAROEN
Journal of Gynecologic Oncology 2015;26(4):293-302
OBJECTIVE: To evaluate the prevalence and features of non-endometrial cancers in Thai endometrial cancer (EC) patients. METHODS: EC patients treated in our institution were identified and the following data were collected: age, EC stage, histopathology, adjuvant therapy, other cancers, living status, and cause of death. RESULTS: The mean age of the 344 patients was 56.8+/-10.8 years. Fifty (14.5%) had other synchronous and metachronous cancers. Mean ages of the patients with or without other cancers were not significantly different, 55.7+/-10.04 years versus 57.1+/-11.0 years, respectively (p=0.358). History of any cancer in the family and tumor in the lower uterine segment were more frequent among the patients with other cancers (6.0% vs. 1.7%, p=0.095; 12.0% vs. 1.0%, p<0.001; respectively). Six patients had > or =2 other cancers. Ovarian, breast, and colon were the three most common other cancers. After a median follow-up of 57.1 months, 18.3% of patients had died: 30.0% of patients with other cancers and 16.3% of those without other cancers. The corresponding EC deaths were 14.0% and 11.2%. The 5-year overall survival was significantly lower in patients who had other cancers: 79.3% (95% confidence interval [CI], 68.3 to 90.3) vs. 86.0% (95% CI, 81.7 to 90.3) than in those without (p=0.023). However, the corresponding disease-specific survival was not significantly different: 85.1% (95% CI, 75.5 to 94.7) compared with 89.0% (95% CI, 85.1 to 92.9), respectively (p=0.514). CONCLUSION: Thai EC patients had a high incidence of other cancers. Overall survival of EC patients who had other cancers was worse than those without, while disease-specific survival was not significantly different.
Breast Neoplasms/mortality/pathology/therapy
;
Chemotherapy, Adjuvant/methods
;
Colonic Neoplasms/mortality/pathology/therapy
;
Disease-Free Survival
;
Endometrial Neoplasms/mortality/*pathology/therapy
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality
;
Neoplasms, Multiple Primary/mortality/*pathology/therapy
;
Neoplasms, Second Primary/mortality/*pathology/therapy
;
Radiotherapy, Adjuvant/methods
;
Tertiary Care Centers/statistics & numerical data
;
Thailand/epidemiology
9.Spontaneous Disruption of Mycotic Aneurysm Involving Innominate Artery.
Sungjin OH ; Young Won YOON ; Gil Jin JANG ; Jung Bae AHN ; Gee pyo HONG ; Gyung hoon GANG ; Myun sik GANG ; Yong uk HONG ; Jung Hae GEE
Journal of Korean Medical Science 2003;18(4):589-591
We report a case of ruptured mycotic aneurysm involving innominate artery requiring an urgent surgical treatment. A 62-yr-old woman presented with fever and dyspnea. Previously, she was diagnosed with colon cancer and received right hemicolectomy and one cycle of adjuvant chemotherapy. On echocardiogram, pericardial effusion was noted and emergency pericardiocentesis was performed. CT scan revealed aortic aneurysm involving ascending aorta and innominate artery, and thrombi surrounding those structures. Patch repair of the defect in the ascending aorta and ringed Goretex graft to bypass the innominate and ascending aorta were performed. We believe that this is the first case of ruptured mycotic aneurysm involving innominate artery.
Aneurysm, Infected/*surgery
;
Aorta/pathology
;
Aortic Aneurysm/surgery
;
Brachiocephalic Trunk/pathology
;
Colonic Neoplasms/drug therapy/surgery
;
Female
;
Human
;
Middle Aged
;
Tomography, X-Ray Computed
;
Transplants
10.Polymorphic reticulosis with colonic lesion: a case report.
Sook Hyang JUNG ; Kyung Hae JUNG ; Chul Ju HAN ; Hyun Chae JUNG ; In Sung SONG ; Kyoo Wan CHOI ; Chung Yong KIM ; Tae Jin KIM ; Yong Il KIM
Journal of Korean Medical Science 1990;5(2):105-109
A 38-year-old man was admitted with a high fever, sore throat, and right upper quadrant pain. Nine months before his admission, he had undergone right hemicolectomy under the impression of intestinal lymphoma. But there had been no evidence of lymphoma on microscopic examination. Under the postoperative diagnosis of inflammatory bowel disease, corticosteroid therapy was tried without response. On the follow-up colonoscopic examination, an ovoid ulcer, with convergence of the surrounding mucosal folds at the descending colon and an irregularly shaped ulcer at the ileocolic anastomotic site, were found. The colonoscopic diagnosis was Behcet's colitis. After pathologic slides of biopsy and surgical specimens obtained from the palatine tonsil and colon were reviewed, the diagnosis of polymorphic reticulosis was made. The patient received anticancer chemotherapy, including cyclophophamide and glucocorticosteroid. To date, colonic involvement of polymorphic reticulosis has not been reported. Because of the similarity of the colonoscopic findings to those of Behcet's colitis, polymorphic reticulosis should be included in the differential diagnosis of inflammatory bowel disease. We assume that this is the first case of polymorphic reticulosis involving the colon with characteristic colonoscopic findings.
Adult
;
Colonic Neoplasms/*diagnosis/drug therapy/pathology
;
Cyclophosphamide/therapeutic use
;
Diagnosis, Differential
;
Drug Therapy, Combination
;
Glucocorticoids/therapeutic use
;
Humans
;
Lymphoproliferative Disorders/*diagnosis
;
Male